Cargando…

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition

Development of inhibitory antibodies to coagulation factor VIII (fVIII) is the primary obstacle to the treatment of hemophilia A in the developed world. This adverse reaction occurs in 20–30% of persons with severe hemophilia A treated with fVIII-replacement products and is characterized by the deve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doshi, Bhavya S., Gangadharan, Bagirath, Doering, Christopher B., Meeks, Shannon L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483154/ https://www.ncbi.nlm.nih.gov/pubmed/23144741 http://dx.doi.org/10.1371/journal.pone.0048172

Ejemplares similares

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
por: Négrier, Claude, et al.
Publicado: (2022)

B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A
por: Delignat, Sandrine, et al.
Publicado: (2019)

Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients
por: Reipert, Birgit M., et al.
Publicado: (2023)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
por: Oh, Jisu, et al.
Publicado: (2013)

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A
por: Johnston, Jennifer M., et al.
Publicado: (2012)

Therapeutic Effects of Kefir Peptides on Hemophilia-Induced Osteoporosis in Mice With Deficient Coagulation Factor VIII
por: Yen, Chih-Ching, et al.
Publicado: (2022)

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
por: Brown, Harrison C, et al.
Publicado: (2014)

Thrombin generation and implications for hemophilia therapies: A narrative review
por: Sidonio, Robert F., et al.
Publicado: (2022)

Thrombin generation: a global coagulation procedure to investigate hypo- and hyper-coagulability
por: Tripodi, Armando
Publicado: (2020)

Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner
por: Batsuli, Glaivy, et al.
Publicado: (2023)

Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice
por: Sarafanov, Andrey G.
Publicado: (2023)

Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century
por: Arruda, Valder R., et al.
Publicado: (2020)

Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review
por: Verhagen, Marieke J. A., et al.
Publicado: (2022)

Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor
por: Childers, Kenneth C., et al.
Publicado: (2023)

Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity
por: Marín, Òscar, et al.
Publicado: (2019)

Activation of blood coagulation and thrombin generation in acute ischemic stroke treated with rtPA
por: Goldman, Sarah, et al.
Publicado: (2017)

Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice
por: Pishko, Allyson M, et al.
Publicado: (2022)

Emerging therapies for hemophilia: controversies and unanswered questions
por: Arruda, Valder R., et al.
Publicado: (2018)

Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor
por: Ronayne, Estelle K., et al.
Publicado: (2021)

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
por: Hermans, Cedric, et al.
Publicado: (2023)

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)

Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis
por: Ziliotto, Nicole, et al.
Publicado: (2018)

Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies
por: Slatter, David A., et al.
Publicado: (2018)

Intrinsic coagulation pathway-mediated thrombin generation in mouse whole blood
por: Konrath, Sandra, et al.
Publicado: (2022)

Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice
por: Lundgren, Taran S., et al.
Publicado: (2022)

Surface functionalization-specific binding of coagulation factors by zinc oxide nanoparticles delays coagulation time and reduces thrombin generation potential in vitro
por: Yang, Jun-Young, et al.
Publicado: (2017)

Thrombin generation in low plasma volumes
por: Bloemen, Saartje, et al.
Publicado: (2018)

Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway
por: Patel, Seema R., et al.
Publicado: (2022)

Human coagulation factor VIII domain-specific recombinant polypeptide expression
por: Choi, Su Jin, et al.
Publicado: (2015)

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A
por: Stem, Christopher, et al.
Publicado: (2021)

Characterization and visualization of murine coagulation factor VIII-producing cells in vivo
por: Hayakawa, Morisada, et al.
Publicado: (2021)

In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype
por: Verhagen, Marieke J.A., et al.
Publicado: (2023)

Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma
por: Persson, Egon, et al.
Publicado: (2019)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Structure of Coagulation Factor II: Molecular Mechanism of Thrombin Generation and Development of Next-Generation Anticoagulants
por: Chinnaraj, Mathivanan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lghvr23dlb09mo3b9g20jc80hg